Company Focusing On Gut Bacteria Drugs Nabs $42.6M In Funding Round
Second Genome plans to use the cash to push its lead drug through a mid-stage clinical trial for inflammation and pain in patients with a bowel disease called ulcerative colitis.
The San Francisco Business Times:
Gut Instinct Leads Peninsula Company To $42 Million
If it takes a microbial village to cause or protect humans from certain diseases, Second Genome Inc. is a little closer to moving to town. The South San Francisco company — developing drugs that seize on changes to the bacterial playground in the gut, known as the microbiome — snagged $42.6 million in a Series B round co-led by the venture capital units of drug giants Pfizer Inc. and Roche. (Leuty, 4/20)